Skip to content

A clinical trial of topical application containing Radix Rubiae for plaque-type psoriasis

Clinical Assessment of a Topical Application Containing Radix Rubiae for Plaque-Type Psoriasis - A Randomized, Double-blind, Vehicle-Controlled and Left-Right Comparison Pilot Study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPC-15007019
Enrollment
Unknown
Registered
2015-09-06
Start date
2015-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Two groups:A topical application containing Radix Rubiae twice a day for 12 weeks versus A vehicle preparation on other side of the psoriatic lesion

Sponsors

School of Chinese Medicine, CUHK
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Men or women aged between 18 and 75 years old; 2. Mild to moderate, bilateral symmetric, chronic plaque psoriasis; and 3. In good general health, as evidenced by blood, liver and renal function tests conducted prior to the commencement of the study.

Exclusion criteria

Exclusion criteria: 1. Chronic plaque psoriasis involving >80% of the body surface; 2. Pustular or generalized erythrodermic psoriasis; 3. Systemic therapy for psoriasis within 30 d of baseline; 4. Use topical medications for psoriasis within 14 d of baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus; 5. UV light therapy within 30 d of baseline; 6. Clinically significant laboratory abnormality in blood, liver or renal functions; 7. A history of sensitive to Chinese herbs or petroleum jelly; 8. Unwillingness to comply with study protocol; and 9. Any other condition that in the opinion of the investigators could compromise the study.

Design outcomes

Primary

MeasureTime frame
PASI scores (area involved, erythema, induration and scaling scores) on the baseline and weeks 6 and 12;

Secondary

MeasureTime frame
Impact of Psoriasis Questionnaire (IPSO) on baseline and weeks 12;SF36 on the baseline and weeks 12;

Countries

China

Contacts

Public ContactLIN Zhi-Xiu
linzx@cuhk.edu.hk+852 39436347

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026